Therapeutic potential of parkin as a tumor suppressor via transcriptional control of cyclins in glioblastoma cell and animal models.

Abstract

Parkin (PK) is an E3-ligase harboring tumor suppressor properties that has been associated to various cancer types including glioblastoma (GBM). However, PK is also a transcription factor (TF), the contribution of which to GBM etiology remains to be established. Methods: The impact of PK on GBM cells proliferation was analyzed by real-time impedance measurement and flow cytometry. Cyclins A and B proteins, promoter activities and mRNA levels were measured by western blot, luciferase assay and quantitative real-time PCR. Protein-protein and protein-promoter interactions were performed by co-immunoprecipitation and by ChIP approaches. The contribution of endogenous PK to tumor progression in vivo was performed by allografts of GL261 GBM cells in wild-type and PK knockout mice. Results: We show that overexpressed and endogenous PK control GBM cells proliferation by modulating the S and G2/M phases of the cell cycle via the trans-repression of cyclin A and cyclin B genes. We establish that cyclin B is regulated by both E3-ligase and TF PK functions while cyclin A is exclusively regulated by PK TF function. PK invalidation leads to enhanced tumor progression in immunocompetent mice suggesting an impact of PK-dependent tumor environment to tumor development. We show that PK is secreted by neuronal cells and recaptured by tumor cells. Recaptured PK lowered cyclins levels and decreased GBM cells proliferation. Further, PK expression is decreased in human GBM biopsies and its expression is inversely correlated to both cyclins A and B expressions. Conclusion: Our work demonstrates that PK tumor suppressor function contributes to the control of tumor by its cellular environment. It also shows a key role of PK TF function in GBM development via the control of cyclins in vitro and in vivo. It suggests that therapeutic strategies aimed at controlling PK shuttling to the nucleus may prove useful to treat GBM.

• Authors: Lila Rouland, Eric Duplan, Lígia Ramos Dos Santos, Aurore Bernardin, Karen S Katula, Guidalberto Manfioletti, Ahmed Idbaih, Frédéric Checler, Cristine Alves da Costa
• Journal: Theranostics (Theranostics) Vol. 11 Issue 20 Pg. 10047-10063 ( 2021) ISSN: 1838-7640 [Electronic] Australia
• PMID: 34815803 (Publication Type: Journal Article, Research Support, Non-U.S. Gov't)
• Copyright: © The author(s).

Chemical References

• Cyclin A
• Cyclin B
• Cyclins
• MicroRNAs
• RNA, Messenger
• Ubiquitin-Protein Ligases
• parkin protein

Topics

• Animals
• Brain Neoplasms (pathology)
• Cell Cycle
• Cell Line, Tumor
• Cell Proliferation (genetics)
• Cyclin A (drug effects, metabolism)
• Cyclin B (drug effects, metabolism)
• Cyclins (genetics)
• Female
• Flow Cytometry (methods)
• Gene Expression (genetics)
• Gene Expression Regulation, Neoplastic (genetics)
• Genes, Tumor Suppressor (physiology)
• Glioblastoma (metabolism, pathology, therapy)
• Humans
• Male
• Mice
• Mice, Knockout
• MicroRNAs (metabolism)
• Models, Animal
• RNA, Messenger
• Ubiquitin-Protein Ligases (therapeutic use)